On Friday, Shares of Alcoa Inc. (NYSE:AA), gained 0.38% to $10.63.
Alcoa, stated solid second quarter 2015 results as the Company’s transformation showed strong progress. Profitability from Alcoa’s growing aerospace and automotive businesses raised year-over-year as mid and downstream investments delivered positive impact. In the upstream, the Primary Metals business was resilient in the face of market headwinds and the Alumina business delivered its strongest first half results in eight years. The Company’s portfolio reshaping is driving results.
Alcoa stated second quarter 2015 net income of $140 million, or $0.10 per share, counting $143 million in restructuring-related charges, primarily to optimize the Company’s upstream portfolio. Year-over-year, second quarter 2015 results compare to net income of $138 million, or $0.12 per share, in second quarter 2014.
Alcoa Inc. produces and manages primary aluminum, fabricated aluminum, and alumina worldwide. The company operates through four segments: Alumina, Primary Metals, Global Rolled Products, and Engineered Products and Solutions.
Shares of Medtronic plc (NYSE:MDT), inclined 1.75% to $74.37, during its last trading session.
Medtronic, declared the launch of the CD HORIZON® SOLERA® VOYAGER(TM) Spinal System for Minimally Invasive Spine procedures. Accessible recently in countries around the world, the CD HORIZON® SOLERA® VOYAGER(TM) System expands upon the transforaminal lumbar interbody fusion (TLIF) procedure by offering multiple, minimally invasive rod insertion options and enabling a seamless 3D-navigated surgical experience. The declaration was made during the 22nd annual international Meeting on Advanced Spine Techniques (IMAST) in Kuala Lumpur, Malaysia.
With the CD HORIZON® SOLERA® VOYAGER(TM) System, surgeons have the flexibility to use either a percutaneous or Wiltse minimally invasive approach for rod insertion depending upon their preference. The system also features a low-profile, extended-tab screw with inner threading, which eases rod insertion and facilitates rod reduction. In addition, the system is part of Medtronic`s Surgical Synergy(TM) Spinal Platform - the most integrated portfolio of navigated surgical technologies - which seeks to minimize the operating room from interruption and constraints and gives surgeons the freedom to focus wholly on their patients.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
Finally, Biogen Inc. (NASDAQ:BIIB), ended its last trade with -2.77% loss, and closed at $388.23.
Biogen, declared it will report second quarter 2015 financial results on Friday, July 24, 2015, before the financial markets open.
Following the release of the financials, the Company will host a live webcast where Biogen administration will talk about the financial results, at 8:30 am ET.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
